[ad_1]
What’s the ideal portfolio for a Stocks and Shares ISA? Some investors prefer the perceived safety of bonds, others put their trust in active fund managers.
If, like me, you have the time and inclination to do due diligence, you likely prefer individual stocks. In addition to the potential for outsized gains, individual stock picking gives me a feeling of control over my own destiny.
With that in mind, here are three leading UK stocks to consider for a retirement-focused ISA.
RELX
RELX is an ideal long-term British retirement holding because it delivers stability through recurring subscription revenues (over 50% of income), high margins, and exceptional free cash flow of ~27% of revenue.
The company has grown net income by 8.59% year-on-year, maintains a 20.5% net profit margin, and has increased dividends for 15 consecutive years. Dividend growth is typically in the high-single-digits and the payout ratio is around 62%.
With £2.59bn in annual free cash flow and £2.61bn operating cash flow, its debt load looks manageable, albeit a bit high.
A more pressing risk is the disruptional threat of generative AI, which could change how professionals access information.
AstraZeneca
AstraZeneca (LSE: AZN) is another standout long-term retirement holding to consider. It offers exceptional stability through a diversified oncology-focused drug portfolio, strong cash flow generation, and a disciplined balance sheet.
The company reported FY 2025 revenue of £46.3bn (up 8%), with Q4 2025 revenue rising 4% to £12.2bn. Looking ahead to FY 2026, the pharma giant anticipates mid-to-high single-digit total revenue growth and low double-digit core EPS growth.
The dividend yield isn’t much at just 1.73%, but the payout ratio of only 46% allows room for growth. Its balance sheet shows total assets of £82.3bn against liabilities of £50.5bn, demonstrating financial resilience.
A key risk is patent expirations, including Farxiga (£6bn annual sales) losing exclusivity, which could pressure revenue if pipeline launches don’t offset the decline.
Diploma
Diploma (LSE: DPLM) offers exceptional stability through diversified exposure to three essential industries: life sciences, industrial controls, and safety. It enjoys strong cash generation and enacts disciplined capital allocation.
The company reported strong FY25 numbers: an 11% rise in revenue to £1,524.5m and adjusted operating profit up 20% to £342.7m. It also has excellent operating margins at around 22.5%. Free cash flow was £247.2m with 105% conversion, while leverage is conservative at 0.8 times net debt/EBITDA.
Like AstraZeneca, it’s a growth-focused stock with a low 1.1% dividend yield. But with just a 43.85% payout ratio and 10.78% average dividend growth over three years, it shows promise.
A key risk is acquisition integration and execution, as Diploma’s growth strategy relies on both organic growth and selective acquisitions in competitive markets.
Final thoughts
When looking for stocks to hold for a decade or longer, it’s important to look beyond the headline growth and income figures. A company that’s up 100% in a year is unlikely to maintain that momentum indefinitely. A stock with a 9% yield probably lacks sufficient coverage and will need to reduce payments soon.
Instead, focus on things like diverse income streams, earnings visibility, and recurring revenues. The three mentioned here fit those criteria, but they aren’t alone — there are many other equally compelling options to consider on the UK market.
Should you invest £5,000 in AstraZeneca Plc right now?
When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca Plc made the list?
Mark Hartley owns shares in AstraZeneca, RELX, and Diploma.
[ad_2]
Source link